Affordable Access

deepdyve-link
Publisher Website

Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.

Authors
  • Vekeman, Francis
  • McKenzie, R Scott
  • Bookhart, Brahim K
  • Laliberté, François
  • Duh, Mei Sheng
  • Tak Piech, Catherine
  • Lefebvre, Patrick
Type
Published Article
Journal
Journal of Medical Economics
Publisher
Informa UK Limited
Publication Date
Mar 01, 2009
Volume
12
Issue
1
Pages
1–8
Identifiers
DOI: 10.3111/13696990802648167
PMID: 19450059
Source
Medline
License
Unknown

Abstract

This study of 10,928 oncology patients receiving chemotherapy reported a dose ratio of 255:1 (units EPO:microg DARB) with 29% lower treatment cost in the EPO group. These findings are similar to those previously reported from published clinical trials and real-world utilisation studies.

Report this publication

Statistics

Seen <100 times